Pharmalot

Pharmalot

The VA approach to buying drugs means patients are less likely to skip medications due to cost

By Ed Silverman

Pharmalot

Florida becomes the latest state to examine Sun Pharma licenses for distributing samples

By Ed Silverman

Pharmalot

Pharmalittle: Few vets were treated with antidepressant Trump touted; Pelosi lashes out at price hikes

By Ed Silverman

Pharmalot

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

By Ed Silverman

Pharma

Pharmalittle: Lab urges FDA to recall all forms of Zantac; end-of-year FDA approval rush has unintended consequence

By Ed Silverman

Pharmalot

It’s ‘business as usual’ as many drug makers boost prices for the new year

By Ed Silverman

Pharmalot

Pharmalittle: FDA failed to police opioid prescribing program; Novo launches plan to mitigate insulin cost

By Ed Silverman

Pharmalot

Most Americans misunderstand approvals and FDA’s role in overseeing drug ads

By Ed Silverman

Pharmalot

Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis

By Ed Silverman

Pharmalot

Up and Down the Ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA approves first Ebola vaccine; two big pharmacy benefit managers are joining forces

By Ed Silverman

Pharmalot

As families in Europe clamor for its pricey gene therapy, Novartis creates a lottery

By Ed Silverman

Pharmalot

Pharmalittle: Novartis plans a lottery for the world’s priciest drug; Trump importation could hit Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Trump proceeds with plan to allow importation; most Americans misunderstand FDA approvals

By Ed Silverman

Pharmalot

Feds says a CVS long-term-care pharmacy improperly refilled prescriptions, jeopardizing patients

By Ed Silverman

Pharmalot

Pharmalittle: Sacklers withdrew $10 billion from Purdue during opioid crisis; Purdue splits from PhRMA

By Ed Silverman

Pharmalot

Lawmakers say a Lilly program to offer half-price insulin is a bust

By Ed Silverman

Pharmalot

Pharmalittle: Novartis abandons asthma drug billed as blockbuster; FDA approves Amarin’s fish-oil pill

By Ed Silverman

Pharmalot

Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case

By Ed Silverman

Pharmalot

U.S. Patent Office removes lawyer from high-profile case involving a Gilead HIV medicine

By Ed Silverman

Pharmalot

PhRMA sues Oregon over drug pricing transparency laws, calling them ‘unconstitutional’

By Ed Silverman

Pharmalot

Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead in HIV drug case

By Ed Silverman

Pharmalot

Pharmalittle: Pharma ad spend skyrockets to defeat drug pricing bill; many antibiotic prescriptions are inappropriate

By Ed Silverman

They did what? Celgene backs out of a $55 million deal to settle claims of thwarting generics

Patient groups say Brazilian proposal to change patent reviews would favor pharma

Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill

Pharmalittle: The inside story of an Ebola vaccine; fewer adults received opioid prescriptions

The VA approach to buying drugs means patients are less likely to skip medications due to cost

Florida becomes the latest state to examine Sun Pharma licenses for distributing samples

Pharmalittle: Few vets were treated with antidepressant Trump touted; Pelosi lashes out at price hikes

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalittle: Lab urges FDA to recall all forms of Zantac; end-of-year FDA approval rush has unintended consequence

It’s ‘business as usual’ as many drug makers boost prices for the new year

Pharmalittle: FDA failed to police opioid prescribing program; Novo launches plan to mitigate insulin cost

Most Americans misunderstand approvals and FDA’s role in overseeing drug ads

Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis

Up and Down the Ladder: The latest comings and goings

Pharmalittle: FDA approves first Ebola vaccine; two big pharmacy benefit managers are joining forces

As families in Europe clamor for its pricey gene therapy, Novartis creates a lottery

Pharmalittle: Novartis plans a lottery for the world’s priciest drug; Trump importation could hit Gilead

Pharmalittle: Trump proceeds with plan to allow importation; most Americans misunderstand FDA approvals

Feds says a CVS long-term-care pharmacy improperly refilled prescriptions, jeopardizing patients

Pharmalittle: Sacklers withdrew $10 billion from Purdue during opioid crisis; Purdue splits from PhRMA

Lawmakers say a Lilly program to offer half-price insulin is a bust

Pharmalittle: Novartis abandons asthma drug billed as blockbuster; FDA approves Amarin’s fish-oil pill

Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

Up and down the ladder: The latest comings and goings

Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case

U.S. Patent Office removes lawyer from high-profile case involving a Gilead HIV medicine

PhRMA sues Oregon over drug pricing transparency laws, calling them ‘unconstitutional’

Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead in HIV drug case

Pharmalittle: Pharma ad spend skyrockets to defeat drug pricing bill; many antibiotic prescriptions are inappropriate